Prophylactic Minimally Invasive Surfactant Evaluation

Launched by ENDEAVOR HEALTH · Aug 22, 2023

Keywords

ClinConnect Summary

The Prophylactic Minimally Invasive Surfactant Evaluation trial is studying whether giving a special treatment called surfactant to very premature babies (those born between 22 and 29 weeks of pregnancy) right after birth can help improve their breathing compared to giving the treatment later if they need it. Surfactant is a substance that helps keep the tiny air sacs in the lungs open, which is especially important for babies born too early who often struggle with breathing problems.

To participate in this study, babies must be born before 30 weeks of pregnancy, and parents need to give their permission beforehand. Unfortunately, babies with certain birth defects or other causes of breathing issues won't be eligible for this trial. If you decide to participate, you can expect that your baby will receive either the surfactant treatment right away or later on, depending on the study's approach. The goal is to find out the best way to help these vulnerable infants breathe better and have healthier outcomes.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Gestational age \<30 weeks
• • Antenatal consent from Parent
• Exclusion Criteria:
• • Congenital anomalies
• • Alternate cause of respiratory distress